Stocks · Korea
017180
KOSPI
Myungmoon Pharm
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-07 basis
Returns and 52-week range
1W+6.48%
1M+5.20%
3M+3.62%
6M-28.88%
1Y-24.21%
YTD-28.10%
52W high2,055원
52W low1,000원
From 52W high-36.01%
Financial results (consolidated)
| Period | Revenue | Operating income | Net income | OP margin |
|---|---|---|---|---|
| 2022 | 1,521억 | 64억 | 80억 | 4.2% |
| 2023 | 1,696억 | 10억 | -49억 | 0.6% |
| 2024 | 1,864억 | 19억 | -38억 | 1.0% |
| 2025 | 1,952억 | 68억 | 14억 | 3.5% |
| Quarterly | ||||
| 2024 4Q | 491억 | 26억 | 2억 | 5.4% |
| 2025 1Q | 459억 | -9억 | -22억 | -2.0% |
| 2025 2Q | 488억 | 57억 | 34억 | 11.7% |
| 2025 3Q | 499억 | 5억 | -7억 | 0.9% |
| 2025 4Q | 508억 | 16억 | 8억 | 3.2% |
| 2026 1Q | 480억 | 3억 | -10억 | 0.6% |
Company
Address: 경기도 화성시 향남읍 제약공단2길 26
Peers in the same sector
Recent filings
- 2026-08-14반기보고서 (2026.06)
- 2026-05-15분기보고서 (2026.03)
- 2026-04-22주요사항보고서(자기주식처분결정) Major
- 2026-03-30[기재정정]사업보고서 (2025.12)
- 2026-03-18사업보고서 (2025.12)
- 2025-11-14분기보고서 (2025.09)
- 2025-08-14반기보고서 (2025.06)
- 2025-05-15분기보고서 (2025.03)
Source: DART (Financial Supervisory Service electronic disclosure)
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.